Financial competing interests were associated with favourable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. J.Clin.Epidemiol. 2016 Dec;80:43-49.
Masking survival biases in observational treatment studies of influenza patients – Wolkewitz, Schumacher published.
WHO Expert committee recommends transfer of Tamiflu from the Core to the Complementary Essential Medicines List.
Early administration of neuraminidase inhibitors in adults hospitalized for influenza does not benefit survival: a retrospective cohort study published in the European Journal of Clinical Microbiology and Infectious Diseases.
16 June 2017
Academy of Medical Sciences publishes report: Action needed to prevent confusion over medicines in relation to tamiflu and statins evidence. Enhancing the use of scientific evidence - full report Download.
WHO downgrades the status of oseltamivir. Mark H Ebell, BMJ 2017; 358.
WHO’s new list focuses on antibiotic resistance, adds expensive drugs, and downgrades Tamiflu. Michael McCarthy BMJ 2017;358.
European Centre for Disease Prevention and Control: Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza.
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - [PDF-1.15 MB].